Eli Lilly signed two major partnerships in Asia that together carry roughly $3.8 billion in potential value. Lilly granted ABL Bio rights to its Grabody platform in a licensing and research collaboration worth up to $2.6 billion and struck a separate $1.2 billion pact with SanegeneBio to use the LEAD delivery platform for metabolic RNAi programs. Lilly disclosed upfronts and platform access; the deals expand its CNS and metabolic pipelines, and signal continued big‑pharma investment in modality platforms that enable BBB crossing and tissue‑targeted RNAi.